title: Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study.
abstract: OBJECTIVE
  To determine imatinib nonadherence rates in patients with gastrointestinal tumors (GIST) over 90 days.
  
  
  METHODS
  A prospective 90-day observational, open-label, multicenter study was carried out of 28 evaluable GIST patients on imatinib. Nonadherence behavior was measured using a 4-item patient interview. Clinicians, patients, and collaterals rated perceived patient adherence on a 0-100 VAS scale.
  
  
  RESULTS
  Nonadherence rates in the 4 weeks prior to baseline and follow-up were 29% (95% CI=26-32) and 24% (95% CI=21-27, p>0.05). Mean VAS ratings of perceived adherence ranged from 95.2 ± 10.2 to 97.3 ± 4.8 (p>0.05 for time and source of rating). Correlations between perceptions of and actual adherence behavior were negative.
  
  
  CONCLUSIONS
  In this first study on imatinib nonadherence in GIST patients, rates were similar to those observed in patients with chronic myeloid leukemia, higher than clinically expected and exceeding meta-analytic estimates for cancer. Nonadherence rates were consistent across the 90-day period. Nonadherence behavior should be assessed by clinicians.
authors.affiliation: University Hospital St.-Luc, Brussels, Belgium.
authors.forename: Filomena
authors.initials: F
authors.lastname: Mazzeo
authors.forename: Lionel
authors.initials: L
authors.lastname: Duck
authors.forename: Eric
authors.initials: E
authors.lastname: Joosens
authors.forename: Luc
authors.initials: L
authors.lastname: Dirix
authors.forename: Christian
authors.initials: C
authors.lastname: Focan
authors.forename: Frédéric
authors.initials: F
authors.lastname: Forget
authors.forename: Sabina
authors.initials: S
authors.lastname: De Geest
authors.forename: Katja
authors.initials: K
authors.lastname: Muermans
authors.forename: Marie-Anne
authors.initials: MA
authors.lastname: VAN Lierde
authors.forename: Karen
authors.initials: K
authors.lastname: Macdonald
authors.forename: Ivo
authors.initials: I
authors.lastname: Abraham
authors.forename: Jacques
authors.initials: J
authors.lastname: De Grève
mesh_terms: D000293:Adolescent; D000328:Adult; D001549:Benzamides; D005260:Female; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases